Leaderboards/Immunotherapy

Immunotherapy

Last updated May 19, 2026

Rising Stars

New and hot

Rising Stars Researchers

1
Hideki Ikeda
Chiba University
678 cit.
2
Divij Mathew
Parker Institute for Cancer Immunotherapy
594 cit.
3
Guojun Wu
Rutgers, The State University of New Jersey
579 cit.
4
Kevin M. Tharp
University of California, San Francisco
558 cit.
5
Xueliang Wang
Sun Yat-sen University
531 cit.
6
Yang Yu
Peking University
495 cit.
7
Gabriel Espinosa-Carrasco
Memorial Sloan Kettering Cancer Center
495 cit.
8
Jaroslav Žák
Scripps Research Institute
489 cit.
9
Thierry André
Sorbonne Université
471 cit.
10
Lisa Derosa
Inserm
465 cit.

Rising Stars Papers

1
Immune evasion through mitochondrial transfer in the tumour microenvironment
Nature|2025
225 cit.
2
Combined JAK inhibition and PD-1 immunotherapy for non–small cell lung cancer patients
Science|2024
197 cit.
3
A core microbiome signature as an indicator of health
Cell|2024
192 cit.
4
Tumor-associated macrophages restrict CD8+ T cell function through collagen deposition and metabolic reprogramming of the breast cancer microenvironment
Nature Cancer|2024
222 cit.
5
Fusobacterium nucleatum facilitates anti-PD-1 therapy in microsatellite stable colorectal cancer
Cancer Cell|2024
176 cit.
6
Pan-cancer single-cell dissection reveals phenotypically distinct B cell subtypes
Cell|2024
164 cit.
7
Intratumoral immune triads are required for immunotherapy-mediated elimination of solid tumors
Cancer Cell|2024
164 cit.
8
JAK inhibition enhances checkpoint blockade immunotherapy in patients with Hodgkin lymphoma
Science|2024
162 cit.
9
Nivolumab plus ipilimumab versus nivolumab in microsatellite instability-high metastatic colorectal cancer (CheckMate 8HW): a randomised, open-label, phase 3 trial
The Lancet|2025
156 cit.
10
Custom scoring based on ecological topology of gut microbiota associated with cancer immunotherapy outcome
Cell|2024
154 cit.

Rising Stars Reagents

Coming soon

Emerging Leaders

Gaining momentum

Emerging Leaders Researchers

1
Jian Zhang
Fudan University Shanghai Cancer Center
810 cit.
2
Boyi Gan
The University of Texas Health Science Center at Houston
713 cit.
3
Liangjing Wang
Sir Run Run Shaw Hospital
536 cit.
4
Linda Duska
University of Virginia
506 cit.
5
Lai Guan Ng
Agency for Science, Technology and Research
500 cit.
6
Sheng Yao
BioReliance (United States)
474 cit.
7
Linghua Wang
The University of Texas MD Anderson Cancer Center
467 cit.
8
Mihai G. Netea
University of Bonn
450 cit.
9
Saman Maleki Vareki
Ontario Institute for Cancer Research
431 cit.
10
Susan M. Chang
University of California, San Francisco
425 cit.

Emerging Leaders Papers

1
NF-κB in biology and targeted therapy: new insights and translational implications
Signal Transduction and Targeted Therapy|2024
1.6k cit.
2
The roles of ferroptosis in cancer: Tumor suppression, tumor microenvironment, and therapeutic interventions
Cancer Cell|2024
475 cit.
3
Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study
The Lancet|2023
645 cit.
4
Microbial metabolite enhances immunotherapy efficacy by modulating T cell stemness in pan-cancer
Cell|2024
357 cit.
5
Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18): a randomised, double-blind, phase 3 clinical trial
The Lancet|2024
337 cit.
6
Deterministic reprogramming of neutrophils within tumors
Science|2024
333 cit.
7
Perioperative Toripalimab Plus Chemotherapy for Patients With Resectable Non–Small Cell Lung Cancer
JAMA|2024
316 cit.
8
Pan-cancer T cell atlas links a cellular stress response state to immunotherapy resistance
Nature Medicine|2023
467 cit.
9
The pathophysiology of sepsis and precision-medicine-based immunotherapy
Nature Immunology|2024
300 cit.
10
Fecal microbiota transplantation plus anti-PD-1 immunotherapy in advanced melanoma: a phase I trial
Nature Medicine|2023
431 cit.

Emerging Leaders Reagents

Coming soon

All-Time Leaders

The canon

All-Time Leaders Researchers

1
X. Shirley Liu
Dana-Farber Cancer Institute
48.2k cit.
2
Laurence Zitvogel
Université Paris-Sud
26.2k cit.
3
Jennifer A. Wargo
The University of Texas MD Anderson Cancer Center
21.7k cit.
4
Thomas F. Gajewski
University of Chicago
20.1k cit.
5
Thomas Powles
Queen Mary University of London
16.3k cit.
6
Zlatko Trajanoski
Innsbruck Medical University
16k cit.
7
Lieping Chen
Mayo Clinic
15k cit.
8
Luc G.T. Morris
Memorial Sloan Kettering Cancer Center
13k cit.
9
Thierry Boon
Ludwig Cancer Research
10.6k cit.
10
Nagahiro Minato
Kyoto University
9.5k cit.

All-Time Leaders Papers

1
TIMER2.0 for analysis of tumor-infiltrating immune cells
Nucleic Acids Research|2020
5.6k cit.
2
Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response
Nature Medicine|2018
5.5k cit.
3
TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells
Nature|2018
5.4k cit.
4
Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors
Science|2017
5.4k cit.
5
Pan-cancer Immunogenomic Analyses Reveal Genotype-Immunophenotype Relationships and Predictors of Response to Checkpoint Blockade
Cell Reports|2017
5.3k cit.
6
Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion
Nature Medicine|2002
5k cit.
7
Gut microbiome modulates response to anti–PD-1 immunotherapy in melanoma patients
Science|2017
4.6k cit.
8
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
Nature Genetics|2019
4.3k cit.
9
Commensal <i>Bifidobacterium</i> promotes antitumor immunity and facilitates anti–PD-L1 efficacy
Science|2015
3.7k cit.
10
A Gene Encoding an Antigen Recognized by Cytolytic T Lymphocytes on a Human Melanoma
Science|1991
3.5k cit.

All-Time Leaders Reagents

Coming soon

Indexing Immunotherapy Reagents

Citation data for reagents in this field is currently compiling.